Overview

* United Therapeutics Q2 2025 revenue grows 12% yr/yr, misses analyst expectations

* Net income for Q2 rises 11% to $309.5 mln

* Co authorizes $1 bln share repurchase, expiring March 2026

Outlook

* Company expects continued double-digit revenue growth for Tyvaso

* United Therapeutics ( UTHR ) anticipates total revenue growth well into the future

* Company expects data from TETON 2 study in September 2025

Result Drivers

* TYVASO DPI GROWTH - Revenue growth driven by increased quantities sold and price increase, supported by Medicare Part D redesign

* NEBULIZED TYVASO SALES - Revenue increase primarily due to higher quantities sold and price adjustments

* ORENITRAM PERFORMANCE - Record quarterly revenue attributed to increased quantities sold and price increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $798.60 $804.30

Revenue mln mln (11

Analysts

)

Q2 EPS $6.41

Q2 Net $309.50

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for United Therapeutics Corp ( UTHR ) is $392.50, about 24.2% above its July 29 closing price of $297.56

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)